Search Results

Lynk Pharmaceuticals is pleased to announce exclusive licensing agreements with Kobe University and with RIKEN Research Institute to develop RAS inhibitors with a novel MOA.

The Laboratory for Bioinformatics Research at the RIKEN Center for Biosystems Dynamics Research developed this method last year.

Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces it has entered into an exclusive distribution agreement with RIKEN Genesis Co., Ltd, a subsidiary of The Sysmex Corporation (Sysmex), in Japan.

Feb. 18, 2020 14:37 UTC LIVERMORE, Calif.--( BUSINESS WIRE )-- S2 Genomics, a manufacturer and provider of automated tissue sample preparation systems, and the RIKEN Center for Integrative Medical Sciences (IMS), a leading genomics research institute, today announced that RIKEN IMS has joined the S2 Genomics Early Technology Access Program to evaluate and further develop single cell sequencing applications on the S2 Genomics Singulator™ tissue preparation system. Achieving hi

Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that an application for partial revision of manufacturing and marketing approval for AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”), an in vitro diagnostic reagent for multiple antineoplastic agents, was submitted in February 2022 (hereinafter referred to as the “Application for Partial Change”).

Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., and Precision Medicine Asia Co., Ltd. announced that the Ministry of Health, Labour and Welfare has approved the AmoyDx® Pan Lung Cancer PCR Panel as a companion diagnostic for TEPMETKO® a Merck KGaA, Darmstadt, Germany product that received approval by the Japanese MHLW in March 2020.

Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., and Precision Medicine Asia Co., Ltd. announced that the AmoyDx® Pan Lung Cancer PCR Panel, an in vitro diagnostic reagent developed as a companion diagnostic for multiple anti-cancer agents, was approved by Ministry of Health, Labour and Welfare for production and marketing in Japan on June 25, 2021.

Researchers with the RIKEN Center for Brain Science and Ochanomizu University evaluated a treatment for stroke that appears to decrease the damage to the brain. The scientists studied the approach in mice.